Insider Transactions in Q1 2025 at Allogene Therapeutics, Inc. (ALLO)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 03
2025
|
Timothy L. Moore Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
14,746
-5.55%
|
$14,746
$1.71 P/Share
|
|
Feb 03
2025
|
Geoffrey M. Parker CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
4,361
-0.33%
|
$4,361
$1.73 P/Share
|
|
Feb 03
2025
|
Earl Martin Douglas SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
6,404
-1.08%
|
$6,404
$1.71 P/Share
|
|
Feb 03
2025
|
Zachary Roberts EVP of R&D |
SELL
Open market or private sale
|
Direct |
18,832
-2.84%
|
$18,832
$1.7 P/Share
|
|
Feb 03
2025
|
David D Chang President and CEO |
SELL
Open market or private sale
|
Direct |
46,003
-0.86%
|
$46,003
$1.68 P/Share
|
|
Jan 24
2025
|
Geoffrey M. Parker CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
173,913
+11.75%
|
-
|
|
Jan 24
2025
|
Earl Martin Douglas SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
144,928
+19.61%
|
-
|
|
Jan 24
2025
|
David D Chang President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
552,174
+9.33%
|
-
|
|
Jan 24
2025
|
Arie Belldegrun Director |
BUY
Grant, award, or other acquisition
|
Direct |
369,957
+14.19%
|
-
|
|
Jan 24
2025
|
Zachary Roberts EVP of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
173,913
+20.81%
|
-
|
|
Jan 24
2025
|
Annie Yoshiyama SVP, Finance |
BUY
Grant, award, or other acquisition
|
Direct |
36,232
+20.8%
|
-
|
|
Jan 21
2025
|
Zachary Roberts EVP of R&D |
SELL
Open market or private sale
|
Direct |
27,199
-5.28%
|
$27,199
$1.78 P/Share
|